secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000899923-25-000045
Event type: earnings
Sentiment:  negative
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q1 revenue down 3% to $196M; net loss of $0.1M; lowers FY2025 guidance
--------------------------------------------------------------------------------

- GAAP net loss $0.1M ($0.00 EPS); adjusted EPS $(0.03). Revenue of $196M declined 3% YoY.
- Prenatal revenue grew 11% YoY; Pharmacogenomics revenue fell 20% due to UnitedHealthcare coverage cut for GeneSight.
- Gross margin 69% (+40 bps YoY) on lab efficiencies; operating loss $29M vs $27.9M YoY.
- Updated FY2025 revenue guidance lowered to $807-823M from $840-860M; adjusted EPS now $(0.02)-$0.02.
- CEO cited challenges in GeneSight and unaffected hereditary cancer; taking steps to reduce costs and drive growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000045/0000899923-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000045/mygn-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000899923-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer